
Boards vote in favor of to begin transition of LMH into Parkview Logansport Hospital
The Logansport Memorial Hospital board, the Cass County Commissioners and Cass County Council voted unanimously in favor of a transfer agreement between LMH and Parkview Health System Monday night during a public hearing at the Cass County 4-H Fairgrounds.
With the acceptance of the transfer agreement, LMH now has a goal of transitioning to Parkview Logansport Hospital by June 30.
The agreement between LMH and Parkview Health System, which is headquartered in Fort Wayne, allows for all of LMH's assets and liabilities to be transferred to Parkview Logansport Hospital. After the transfer is complete, LMH would cease doing business as a county hospital and terminate and dissolve. All in accordance with Indiana Code 16-22-3-18. Parkview Logansport Hospital would take over the assets and liabilities as well as operation of the hospital.
Richard Church, chief growth and strategy officer at Parkview Health, said that Parkview would invest approximately $37 million into the Logansport hospital and the community. He said Parkview would pay back a $3 million loan the county had given LMH as well as other outstanding debt the hospital had accrued. Parkview will invest a minimum of $15 million into new equipment for the hospital and $10 million into converting to the Epic medical record system.
The public hearing consisted of two presentations, one by Tara McVay, president and CEO of Logansport Memorial Hospital, and one by Church. After the presentations, audience members had an opportunity to ask questions and express concerns—of which only a limited number of people did—and then the three boards voted to approve the transfer agreement.
'I think it's nice to have a plan,' McVay said after the hearing. 'I've been a long-term employee at the hospital. I've been here just under 28 years. I love the hospital and being a community hospital is important to me but then I had to stop and think about what is important to me. Continuing to have quality care, continuing to have multiple core service lines and continuing to take care of our employees. This is what I care about the hospital and the community.'
McVay said they will evaluate the hospital over the next two-and-half months alongside Parkview to determine how the transition will work and what it means for the community. She expected the transition to take from 12 to 24 months to be completed.
During her presentation, McVay focused on the difficulties the hospital had encountered over the past few years.
'We've had the quality care,' she said. 'We've provided the service. We continue to keep our service lines open to make sure we are providing that care but we struggled significantly with financial resources to do that.'
McVay said the hospital averaged approximately 3.5 million in available cash for operations, which equals about 12 to 16 days. She said that if money stopped coming into the hospital, then they would only be able to pay their bills for 16 days.
Throughout 2024, the hospital lost on average nine thousand dollars a day, she said, adding that the loss had improved from the prior two years but was still too much.
'We are a very important part of this community,' she said. 'We employ many people. We are an important economic fabric of this community. We need to have better financial stability.'
Because of those financial difficulties, the hospital had not been able to upgrade equipment over the past few years though it did have to make some building improvements over that time.
Another contributing factor included Medicaid reimbursements having not increased in 30 years, she said.
'We have been surviving for the last several years,' McVay said. 'Our employees, our community, our health care system in this area deserves to thrive.'
McVay ended her presentation buy showing how LMH's and Parkview's values aligned in terms of the supporting rural health care, valuing quality care and operating as nonprofit hospitals.
Following McVay's presentation, Church presented on how a partnership with Parkview would benefit the hospital.
Church said that Parkview serves a 22 county region that extends into many rural areas.
'This is kind of core to who we are,' he said. 'This is what we believe part of our system's mission is—to be one of the best systems in the country to delivering health care in rural communities.'
Church said one of the advantages of being a larger hospital system is being able to overcome disruptions such as COVID or unexpected Medicaid cuts on the state or federal level. He said such an unforeseen turn could cause a hospital like LMH to have to close its doors due to the small amount of cash it has on hand. He said the size of the Parkview Health system would help bring financial stability to the Logansport hospital and assist them in riding out any complicated periods or shake ups.
Church said the primary goals of Parkview would be strengthening the Logansport community through new market growth, ensuring continued high quality local access to care, sustaining employment, stabilizing financials and helping the Logansport hospital do more by being more efficient.
'You will still have community representatives from your local community that are on the board at the hospital,' he said. '(Parkview) will have a couple of people that will join and at the health system level we will provide some oversight but you will still have local folks that you can sit down with.'
'Logansport is a fantastic community with an incredible team of caregivers at its hospital,' said Dr. Ray Dusman, Parkview Health President of Physician and Clinical Enterprise, said in a press release Tuesday morning. 'As not-for-profits, our organizations are charged with caring for and reinvesting in our communities, and we are eager to work together to make an impact.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
a day ago
- Business Wire
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. 'The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer,' said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. 'Importantly, we also saw an extension in the duration of time before pain progressed. Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of Tumor Treating Fields therapy concomitant with gemcitabine and nab-paclitaxel to become a standard of care for unresectable, locally advanced pancreatic cancer.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. 'The encouraging data from the Phase 3 PANOVA-3 study demonstrate a meaningful improvement in outcomes for patients with unresectable, locally advanced pancreatic cancer—including pain reduction and a statistically significant improvement in overall survival,' said Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. 'Pancreatic cancer remains one of the most challenging cancers to treat globally, with approximately 134,000 new cases diagnosed annually in China alone. Zai Lab participated in this trial and looks forward to continuing our collaboration with Novocure to bring this innovative therapy to patients in China as quickly as possible.' 'Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis,' said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. 'The results shared today at ASCO and in the Journal of Clinical Oncology demonstrate that Tumor Treating Fields therapy improved overall survival and pain-free survival in unresectable, locally advanced pancreatic cancer. We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy.' Results from PANOVA-3 In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement [hazard ratio (HR) 0.82; p=0.039 (N=571)]. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. Pancreatic cancer can cause significant pain as the disease progresses and managing pain is a key clinical challenge. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with 68.1% [95% CI: 62.0–73.5] compared to those who received gemcitabine and nab-paclitaxel alone, 60.2% [95% CI: 54.2–65.7], p=0.029. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months [95% CI: 10.3–22.8] compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone [95% CI: 7.4–12.7]; HR 0.74 [95% CI: 0.56–0.97], p=0.027. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death. Quality of life was also measured as a secondary endpoint. Analyses were performed for all patients using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum. Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields therapy concomitant with gemcitabine and nab-paclitaxel compared to the gemcitabine and nab-paclitaxel alone group. Full analysis of the quality of life results in PANOVA-3 will be shared at a future scientific conference. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Data Presentation & Publication Details The PANOVA-3 data, (LBA 3500) Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), will be presented today by Dr. Picozzi in Hall D1 during the 3:00 – 6:00 p.m. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary oral session. The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study, will be available online at Novocure Investor Event Novocure will host an investor event featuring Dr. Picozzi and Novocure leadership after the oral presentation. Event details and a link to a live webcast of the event are available on the investor relations page of For more information or to request in-person attendance, please contact Novocure investor relations at investorinfo@ Regulatory & Ongoing Clinical Study of TTFields for Pancreatic Cancer Novocure plans to file for regulatory approval for use of TTFields therapy in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 in the U.S. in the second half of 2025. The company also plans to file for regulatory approval in EU, Japan and other key markets. Novocure continues to follow patients in its Phase 2 PANOVA-4 trial exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in the first half of 2026. About PANOVA-3 PANOVA-3 is an international prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About PANOVA-4 PANOVA-4 is an international, multi-center, Phase 2 clinical trial designed to test the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The primary endpoint is disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study is designed to enroll 76 patients and enrollment is complete. About Pancreatic Cancer in China Pancreatic cancer is one of the most common and deadliest cancers globally. In China, there were an estimated 134,374 new cases in 2022, and it is now the eighth most common cancer type 1. The current median survival of patients with locally advanced, unresectable pancreatic cancer is nine to twelve months, and the five-year survival rate was 7.2% 2, making it the malignancy with the lowest survival rate in China. 1 Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590. 2 Hu JX, Zhao CF, Chen WB et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27: 4298-4321. About Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Zai Lab Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for developing and commercializing TTFields therapy, the potential benefits of TTFields therapy, and the potential treatment of pancreatic cancer. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at
Yahoo
a day ago
- Yahoo
Surviving dogs, a backcountry rescue: Story of deadly plane crash in Idaho retold
For former U.S. Forest Service smokejumper Wayne Williams, the best part of reading an Idaho author's recent book was finding out what happened to the dog at the end. Williams was one of the first responders who helped rescue survivors, recover the deceased and clear the wreckage of the June 1979 plane crash chronicled in the book 'In Selway Shadows: Last Flight of 148Z,' written by Richard Holm, a backcountry pilot based in McCall, and published in March. Williams, a U.S. Forest Service smokejumper, spent the first night at the scene of the crash camped beside the dog, Bess, a retriever-German shepherd mix who'd sustained a fractured leg when the plane went down in the Selway River. After the dog was evacuated the next day by plane, Williams never learned what happened to her. Holm tracked down details — like what happened to Bess — by poring over documents and interviewing witnesses, including the two survivors of the crash to create the most complete account of the event, which killed 10 people. Holm's book offers a look at life before the flight, the crash's impact on survivors and the victims' families and the ways a wilderness community rallied to recover the wreckage from a near-impossible crash site. It also details an investigation that shows how this became the deadliest aviation incident in Forest Service history. 'It's a tragic story, but it's also one of a lot of heroism,' Holm told the Idaho Statesman in a phone interview. 'The larger story is made up of all these incredible smaller stories that are just truly unbelievable.' Holm first heard about Flight 148Z while working on a book about the history of Idaho's backcountry airstrips. But the topic 'kind of fell in my lap again,' he said, through a friend he'd met in his research — Cindy Bartholf, a former archaeologist with the Nez Perce National Forest near Grangeville in North Idaho. Bartholf contacted Holm in 2016 about an airplane data tag that a Florida man had 'returned' to the forest. He said he found it in the Selway River in the fall of 1979 during a rafting trip and believed it to be from Flight 148Z. Bartholf was puzzled with the data tag, which was stamped with information that identified the plane as a U.S. Army Air Forces and Douglas Aircraft C-47A. Flight 148Z was a different type of aircraft, a Douglas Aircraft DC-3. Holm suspects the artifact is authentic. The two aircraft were similar — the C-47A was used in World War II as a military plane, while the DC-3 was considered its civilian equivalent. In his book, Holm said Flight 148Z could have been built as a C-47A during the war and converted to a non-military plane used by the Forest Service. Regardless, the aluminum tag sparked his interest in the crash. And Bartholf was the perfect contact. Her father, Art Seamans, led the Selway-Bitterroot Wilderness's Moose Creek Ranger District in 1979. He had ordered the ill-fated aircraft for a training that was planned at the remote ranger station. Bartholf and her mother and sister were slated to be on Flight 148Z. 'Fortunately, we flew in on an earlier flight, on a Cessna 206, with a local air service,' Bartholf told the Statesman in an email. 'Knowing that we could have been on the plane has and will forever haunt me. God had a different plan for us.' When the DC-3 took off from Grangeville on June 11, 1979, it carried 10 passengers, two pilots and two dogs. All the passengers sat along the lefthand side of the plane, while cargo was arranged on the right. One of the survivors, then-17-year-old Moose Creek assistant station guard Bryant Stringham, later told Holm he recalled watching the scenery of the Idaho wilderness from the windows across the aircraft as his beagle, Beetle, seemed agitated and cocked his head back and forth at the engine across the aisle. Holm said halfway into the 30-minute flight, the pilots noticed an issue with the engine on the left side of the plane, which had overheated. The pilots turned it off, he said, knowing the airplane was certified to fly on a single engine if it had to. Within about a minute, the right engine exploded in front of the passengers' eyes and fell away from the plane. The pilots fought to land the plane in the Selway as rafters and hikers — including a Spokesman-Review photographer who snapped a famous photo — watched its descent. Only three people made it out of the plane: Stringham; helitack firefighter Charlie Dietz, 26; and Nez Perce National Forest engineer Andy Taylor, 59. Taylor died of injuries from the crash as Williams' smokejumper team administered first aid at the scene. Both dogs, Bess and Beetle, also survived. Beetle was found by a hiker and returned to Stringham, who, after helping the other two surviving passengers, went for help. He rode on horseback to the Moose Creek Ranger Station before being put on another plane back to Grangeville with Beetle. The Army National Guard airlifted Dietz, who was badly injured in the crash, by helicopter to Spokane. The smokejumper team had settled down to camp for the night, and some of them sheltered Bess and built a fire to keep her comfortable. A helicopter took Bess back to Grangeville the next day. It was the last Williams heard of the dog until he read Holm's book. Bess had belonged to Catherine 'Tykie' Hodgin, who was flying out to staff the fire lookout at Shissler Peak. Hodgin died in the crash. Bess was treated for a fractured leg and adopted by Hodgin's friend and ex-husband, Dan Hodgin, Holm said in the book. That day, Williams' smokejumper team was told to return to base in Missoula, Montana. But Williams and four others asked to stay. 'We didn't have any idea what we would be up against, most of us,' Williams told the Statesman in a phone interview. He remained in Moose Creek for a week, initially recovering aircraft debris but soon recovering the bodies of the victims. He worked alongside employees from other Forest Service districts, including Moose Creek, where many of the victims were already well-known. The remote area was one of few wilderness districts in the Forest Service at the time, and the primitive requirements there forced employees to work closely and forged a deep sense of pride in their work, Williams said. The wilderness proved especially challenging when it came to removing the remaining wreckage of the airplane from the fast-moving Selway River. Officials leaned on two Moose Creek employees who had built many of the primitive-style bridges in the wilderness area, for a solution. Holm said the pair crafted 'block and tackle' pulley systems that helped lift both aircraft engines, the tail and the wing from the river. Holm's book delves into the Forest Service investigation that identified what went wrong with both engines — a series of 'very poor maintenance' and other repair and inspection errors for which no individual or agency ever took responsibility, Holm said. He wove the technical aviation story alongside the stories of the people who were lost, those who survived and the dozens more who were impacted by the crash. Williams and Bartholf said they were taken back to June 1979 as they spoke with Holm, and again when they read 'In Selway Shadows' and saw the incident from other perspectives. For Bartholf, it was an emotional journey that reminded her of summers spent on the Moose Creek Ranger District with her family. She shared documents with Holm that her parents had saved, including funeral programs, letters to victims' families and her father's handwritten manifest for the flight. She said it was 'surreal' to read about her family's experiences but applauded Holm's ability to bring Moose Creek to life and show the human element of a story that, until now, had only been told in bits and pieces. Williams said he recently met with another smokejumper from the crew that responded on the day of the crash to discuss the book. The men talked about how the book brought back details they'd forgotten in the decades since the crash, and taught them things they never knew — like what happened to Bess. 'It was in some sense sort of enlightening in one way and sort of sad in another,' Williams said. 'I know more now about the people who died on that aircraft than I did on the day the rescue took place. The book introduced me to those individuals who I'd never known.'


Business Wire
a day ago
- Business Wire
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. 'The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer,' said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. 'Importantly, we also saw an extension in the duration of time before pain progressed. Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of Tumor Treating Fields therapy concomitant with gemcitabine and nab-paclitaxel to become a standard of care for unresectable, locally advanced pancreatic cancer.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients treated with TTFields. 'Most people with pancreatic cancer are diagnosed with advanced disease, which is very difficult to treat and only about 1 in 10 people are alive five years after diagnosis,' said Nicolas Leupin, MD, PhD, Chief Medical Officer, Novocure. 'The results shared today at ASCO and in the Journal of Clinical Oncology demonstrate that Tumor Treating Fields therapy improved overall survival and pain-free survival in unresectable, locally advanced pancreatic cancer. We plan to submit these data to the FDA in the second half of 2025 to support a premarket approval for Tumor Treating Fields therapy.' Results from PANOVA-3 In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement [hazard ratio (HR) 0.82; p=0.039 (N=571)]. TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints including the one-year survival rate and pain-free survival. Pancreatic cancer can cause significant pain as the disease progresses and managing pain is a key clinical challenge. The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group with 68.1% [95% CI: 62.0–73.5] compared to those who received gemcitabine and nab-paclitaxel alone, 60.2% [95% CI: 54.2–65.7], p=0.029. Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months [95% CI: 10.3–22.8] compared to a median 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone [95% CI: 7.4–12.7]; HR 0.74 [95% CI: 0.56–0.97], p=0.027. This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until an increase of 20 or more points was reported by patients on a visual scale for pain or until death. Quality of life was also measured as a secondary endpoint. Analyses were performed for all patients using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with the pancreatic cancer specific PAN26 addendum. Deterioration-free survival in global health status, pain and digestive problems were significantly improved in patients receiving TTFields therapy concomitant with gemcitabine and nab-paclitaxel compared to the gemcitabine and nab-paclitaxel alone group. Full analysis of the quality of life results in PANOVA-3 will be shared at a future scientific conference. There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms. TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs. Data Presentation & Publication Details The PANOVA-3 data, (LBA 3500) Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC), will be presented today by Dr. Picozzi in Hall D1 during the 3:00 – 6:00 p.m. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary oral session. The Phase 3 PANOVA-3 publication in the Journal of Clinical Oncology, Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study, will be available online at Novocure Investor Event Novocure will host an investor event featuring Dr. Picozzi and Novocure leadership after the oral presentation. Event details and a link to a live webcast of the event are available on the investor relations page of For more information or to request in-person attendance, please contact Novocure investor relations at investorinfo@ Regulatory & Ongoing Clinical Study of TTFields for Pancreatic Cancer Novocure plans to file for regulatory approval for use of TTFields therapy in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3 in the U.S. in the second half of 2025. The company also plans to file for regulatory approval in EU, Japan and other key markets. Novocure continues to follow patients in its Phase 2 PANOVA-4 trial exploring the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment with data anticipated in the first half of 2026. About PANOVA-3 PANOVA-3 is an international, prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields) therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About PANOVA-4 PANOVA-4 is an international, multi-center, Phase 2 clinical trial designed to test the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. The primary endpoint is disease control rate. Secondary endpoints include overall survival, progression-free survival, one-year survival rate, objective response rate, progression-free survival at six months, duration of response, and toxicity. The study is designed to enroll 76 patients and enrollment is complete. About Pancreatic Cancer Pancreatic cancer is one of the most lethal cancers and is the third most frequent cause of death from cancer in the U.S. i While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing. ii It is estimated that approximately 67,000 patients are diagnosed with pancreatic cancer each year in the U.S. iii Pancreatic cancer has a five-year relative survival rate of just 13%. iv Physicians use different combinations of surgery, radiation and pharmacological therapies to treat pancreatic cancer, depending on the stage of the disease. For patients with locally advanced pancreatic cancer involving encasement of arteries but no extra-pancreatic disease, the standard of care is surgery followed by chemotherapy with or without radiation. Unfortunately, most locally advanced cases are diagnosed when the cancer is no longer operable, generally leaving chemotherapy with or without radiation as the only treatment option. About Tumor Treating Fields Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe' or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.